PMID- 34440488
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210831
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 11
IP  - 8
DP  - 2021 Jul 26
TI  - Molecular Targets for Biological Therapies of Severe Asthma: Focus on 
      Benralizumab and Tezepelumab.
LID - 10.3390/life11080744 [doi]
LID - 744
AB  - Asthma is a heterogeneous respiratory disease characterized by usually reversible 
      bronchial obstruction, which is clinically expressed by different phenotypes 
      driven by complex pathobiological mechanisms (endotypes). In recent years several 
      molecular effectors and signaling pathways have emerged as suitable targets for 
      biological therapies of severe asthma, refractory to standard treatments. Indeed, 
      various therapeutic mono-clonal antibodies currently allow one to intercept at 
      different levels the chain of pathogenic events leading to type 2 (T2) airway 
      inflammation. Pro-allergic immunoglobulin E (IgE) is the first molecule against 
      which an anti-asthma monoclonal antibody (omalizumab) was developed; today other 
      targets are successfully being exploited by biological treatments for severe 
      asthma. In particular, pro-eosinophilic interleukin 5 (IL-5) can be targeted by 
      mepolizumab or reslizumab, whereas benralizumab is a selective blocker of IL-5 
      receptor, and IL-4 and IL-13 can be targeted by dupilumab. Besides these drugs, 
      which are already available in medical practice, other biologics are under 
      clinical development such as those targeting innate cytokines, including the 
      alarmin thymic stromal lymphopoietin (TSLP), which plays a key role in the 
      pathogenesis of type 2 asthma. Therefore, ongoing and future biological therapies 
      are significantly changing severe asthma management on a global level. These new 
      therapeutic options make it possible to implement phenotype/endotype-specific 
      treatments, which are delineating personalized approaches precisely addressing 
      the individual traits of asthma pathobiology. The aim of the study is to review 
      the immunopathology and treatment efficacy for severe asthma and focused on new 
      biological agents with benralizumab (anti-IL-5) and tezepelumab (anti-TSLP).
FAU - Cheng, Shih-Lung
AU  - Cheng SL
AUID- ORCID: 0000-0003-0111-3157
AD  - Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei 10042, 
      Taiwan.
AD  - Department of Chemical Engineering and Materials Science, Yuan Ze University, 
      Taoyuan City 320315, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210726
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC8399988
OTO - NOTNLM
OT  - interleukin-5
OT  - severe asthma
OT  - thymic stromal lymphopoietin
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
PMCR- 2021/07/26
CRDT- 2021/08/27 01:07
PHST- 2021/06/30 00:00 [received]
PHST- 2021/07/16 00:00 [revised]
PHST- 2021/07/19 00:00 [accepted]
PHST- 2021/08/27 01:07 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
PHST- 2021/07/26 00:00 [pmc-release]
AID - life11080744 [pii]
AID - life-11-00744 [pii]
AID - 10.3390/life11080744 [doi]
PST - epublish
SO  - Life (Basel). 2021 Jul 26;11(8):744. doi: 10.3390/life11080744.